Skip to content
Portage BioTech, LLC.
Portage BioTech, LLC.Portage BioTech, LLC.
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • details of key advisors
    • press releases
  • contact
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • details of key advisors
    • press releases
  • contact

Daily Archives: October 16, 2020

Consolidated Interim Financial Statements For the three months ended June 30, 2020

Financial and Regulatory ReportsBy Portage Biotech, IncOctober 16, 2020
...

PORTAGE ANNOUNCES FILING OF Q1 INTERIM FINANCIAL STATEMENTS; CORRECTION TO SALVARX LOAN NOTE SETTLEMENT ANNOUNCEMENT

Press ReleaseBy Portage Biotech, IncOctober 16, 2020
...

MANAGEMENT’S DISCUSSION AND ANALYSIS Prepared as of October 15, 2020

Financial and Regulatory ReportsBy Portage Biotech, IncOctober 16, 2020
...
Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top